Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection

NCT02178592 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Human Immunodeficiency Virus
HIV Infections

Interventions

DRUG: DTG 50 mg
DRUG: EFV 600 mg

Sponsor

ViiV Healthcare

Collaborators

[object Object]